These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10897126)

  • 21. Clinical impact of ex vivo differentiated myeloid precursors after high-dose chemotherapy and peripheral blood progenitor cell rescue.
    Zimmerman TM; Lee WJ; Bender JG; Schilling M; Smith SL; Van Epps DE; Williams SF
    Bone Marrow Transplant; 2000 Sep; 26(5):505-10. PubMed ID: 11019839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
    Wong R; Rondon G; Saliba RM; Shannon VR; Giralt SA; Champlin RE; Ueno NT
    Bone Marrow Transplant; 2003 Jun; 31(12):1157-63. PubMed ID: 12796796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma.
    Kozuka T; Kiura K; Katayama H; Fujii N; Ishimaru F; Ikeda K; Ueoka H; Hamasaki S; Yoshino T; Kashihara Y; Date H; Tanimoto M; Harada M
    Anticancer Res; 2002; 22(5):2939-44. PubMed ID: 12530021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003.
    Gratwohl A; Baldomero H; Schmid O; Horisberger B; Bargetzi M; Urbano-Ispizua A
    Bone Marrow Transplant; 2005 Oct; 36(7):575-90. PubMed ID: 16086045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma].
    Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W
    Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
    Schulman KA; Stadtmauer EA; Reed SD; Glick HA; Goldstein LJ; Pines JM; Jackman JA; Suzuki S; Styler MJ; Crilley PA; Klumpp TR; Mangan KF; Glick JH
    Bone Marrow Transplant; 2003 Feb; 31(3):205-10. PubMed ID: 12621482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Peripheral blood stem cell transplantation as an interdisciplinary challenge--theory and practice].
    Cassens U; Jackisch C; Garritsen HS; Schneider HP; Sibrowski W
    Zentralbl Gynakol; 1998; 120(8):367-72. PubMed ID: 9757543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral blood progenitor cell transplantation: economic issues.
    Yee GC
    Pharmacotherapy; 1998; 18(1 Pt 2):9S-16S. PubMed ID: 9473174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
    Carlson LE; Koski T; Glück S
    Bone Marrow Transplant; 2001 May; 27(9):989-98. PubMed ID: 11436111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
    Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).
    Hertenstein B; Hambach L; Bacigalupo A; Schmitz N; McCann S; Slavin S; Gratwohl A; Ferrant A; Elmaagacli A; Schwertfeger R; Locasciulli A; Zander A; Bornhäuser M; Niederwieser D; Ruutu T;
    Haematologica; 2005 Jul; 90(7):969-75. PubMed ID: 15996934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer.
    De Rosa L; Lalle M; Pandolfi A; Pescador L
    Bone Marrow Transplant; 2001 May; 27(10):1031-5. PubMed ID: 11438817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
    J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
    Sawada H; Wake A; Yamasaki Y; Izumi Y
    Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
    Zander AR; Kröger N; Schmoor C; Krüger W; Möbus V; Frickhofen N; Metzner B; Schultze W; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Trümper L; Kreienberg R; Carstensen M; Schmidt EH; Jänicke F; Schumacher M; Jonat W
    J Clin Oncol; 2004 Jun; 22(12):2273-83. PubMed ID: 15111618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outpatient sequential high dose alkylation with stem cell support for patients with advanced breast cancer: a phase I-II study.
    Genre D; Viens P; Gravis G; Bertucci F; Cowen D; Novakovitch G; Derméche S; Chabannon C; Oziel-Taieb S; Camerlo J; Houvenaeghel G; Jacquemier J; Maraninchi D
    Anticancer Res; 2000; 20(3B):2033-40. PubMed ID: 10928147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.